Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer

Table 1 Impact of SDPR expression and clinic pathologic characteristics in lung adenocarcinoma

Clinicopathologic variable^a	HR	95% CI	P value
a. SDPR expression associations with overall survival in KRAS-mutant patients (GSE72094) using Cox regression
Expression (low vs high)	0.55	0.31–0.98	0.04

Clinicopathologic variable^b	HR	95% CI	P value
b. Multivariate survival model in KRAS-mutant patients (GSE72094) using Cox regression
SDPR expression (low vs high)	0.53	0.29–0.96	0.04
Gender	0.77	0.41–1.45	0.42
Smoking	0.75	0.37–1.51	0.42
Pathological stage (I vs II–IV)	2.05	1.13–3.70	0.02
c. Impaction of SDPR and clinicopathologic characteristics on overall survival

Clinicopathologic variable^a	HR	95% CI	P value
d. SDPR expression associations with overall survival in lung cancer patients (GSE72094) using Cox regression
SDPR expression (low vs high)	0.44	0.30–0.64	< 0.001

Clinicopathologic variable^b	HR	95% CI	P value
e. Multivariate survival model using Cox regression
SDPR expression (low vs high)	0.47	0.32–0.70	< 0.001
Gender	0.55	0.38–0.82	< 0.001
Smoking	0.78	0.503–1.21	0.26
Pathological stage			< 0.001
Stage I	0.75	0.16–3.54	0.71
Stage II	0.25	0.12–0.54	< 0.001
Stage III	0.48	0.21–1.07	0.07
Stage IV	0.82	0.37–1.83	0.63
f. Impaction of SDPR and clinicopathologic characteristics on overall survival

ISSN: 1475-2867